Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.
Frontiers in immunology – January 01, 2025
Source: PubMed
Summary
Remarkable neuroimaging revealed significant brain repair in two multiple sclerosis patients after ibogaine treatments. This psychedelic medicine led to substantial lesion reduction and signs of neuroregeneration, suggesting ibogaine and its metabolite noribogaine may promote neural healing and modulate circuits affected by MS. A promising new direction for treatment.
Abstract
Multiple sclerosis (MS) is a debilitating neurodegenerative disease characterized by demyelination and neuronal loss. Traditional therapies often fail to halt disease progression or reverse neurological deficits. Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. Patient A demonstrated substantial lesion shrinkage and decreased Apparent Diffusion Coefficient (ADC) values, suggesting remyelination and reduced inflammation. Both patients exhibited cortical and subcortical alterations, particularly in regions associated with pain and emotional processing. These findings suggest that ibogaine may promote neuroplasticity and modulate neurocircuitry involved in MS pathology.